Maze Therapeutics, Inc.

Contributing Author

Recent Articles by Maze Therapeutics, Inc.

Jan-05	Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference MAZE GlobeNewswire
Nov-06	Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights MAZE GlobeNewswire
Nov-06	Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week MAZE GlobeNewswire
Nov-04	Maze Therapeutics to Participate in Four Upcoming Investor Conferences MAZE GlobeNewswire
Oct-06	Maze Therapeutics Appoints Industry Veteran Herve Hoppenot as Chairman of the Board of Directors MAZE GlobeNewswire
Sep-11	Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement MAZE GlobeNewswire
Sep-11	Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) MAZE GlobeNewswire
Sep-02	Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer MAZE GlobeNewswire
Aug-12	Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights MAZE GlobeNewswire
Jul-10	Maze Therapeutics to Participate in Two Upcoming Investor Conferences MAZE GlobeNewswire
May-29	Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference MAZE GlobeNewswire
May-14	Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones MAZE GlobeNewswire
May-13	Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference MAZE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.